KOBAYASHI PHARM
There is no Profile data available for KOY.MU.
KOBAYASHI PHARM (KOY) - Net Assets
Latest net assets as of June 2025: €208.24 Billion EUR
Based on the latest financial reports, KOBAYASHI PHARM (KOY) has net assets worth €208.24 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€260.71 Billion) and total liabilities (€52.47 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €208.24 Billion |
| % of Total Assets | 79.87% |
| Annual Growth Rate | 4.79% |
| 5-Year Change | 16.92% |
| 10-Year Change | N/A |
| Growth Volatility | 2.18 |
KOBAYASHI PHARM - Net Assets Trend (2017–2024)
This chart illustrates how KOBAYASHI PHARM's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for KOBAYASHI PHARM (2017–2024)
The table below shows the annual net assets of KOBAYASHI PHARM from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €213.47 Billion | +4.23% |
| 2023-12-31 | €204.82 Billion | +3.50% |
| 2022-12-31 | €197.90 Billion | +1.18% |
| 2021-12-31 | €195.60 Billion | +7.13% |
| 2020-12-31 | €182.58 Billion | +5.75% |
| 2019-12-31 | €172.66 Billion | +3.86% |
| 2018-12-31 | €166.25 Billion | +8.09% |
| 2017-12-31 | €153.81 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to KOBAYASHI PHARM's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 41.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €208.24 Billion | 97.55% |
| Other Components | €5.23 Billion | 2.45% |
| Total Equity | €213.47 Billion | 100.00% |
KOBAYASHI PHARM Competitors by Market Cap
The table below lists competitors of KOBAYASHI PHARM ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
G2 Technologies Corp
PINK:GTGEF
|
$284.98K |
|
MEDCAW INVESTMENTS LS-01
F:U09
|
$285.10K |
|
EVP Capital Inc.
V:EVP-P
|
$285.20K |
|
DATA MODUL
BE:DAM
|
$285.22K |
|
STMICROELECTRONICS - Dusseldorf Stock Exchang
DU:SGM
|
$284.84K |
|
Shellron Capital Ltd.
V:SHLL-P
|
$284.80K |
|
Equinor ASA Navne-Aks.
STU:DNQA
|
$284.78K |
|
Averbuch Formica Center Ltd
TA:AVER
|
$284.46K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in KOBAYASHI PHARM's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 204,816,000,000 to 213,466,000,000, a change of 8,650,000,000 (4.2%).
- Net income of 10,067,000,000 contributed positively to equity growth.
- Dividend payments of 7,505,000,000 reduced retained earnings.
- Other factors increased equity by 6,088,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €10.07 Billion | +4.72% |
| Dividends Paid | €7.50 Billion | -3.52% |
| Other Changes | €6.09 Billion | +2.85% |
| Total Change | €- | 4.22% |
Book Value vs Market Value Analysis
This analysis compares KOBAYASHI PHARM's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €1948.27 | €30.40 | x |
| 2018-12-31 | €2102.46 | €30.40 | x |
| 2019-12-31 | €2208.93 | €30.40 | x |
| 2020-12-31 | €2335.91 | €30.40 | x |
| 2021-12-31 | €2516.20 | €30.40 | x |
| 2022-12-31 | €2603.46 | €30.40 | x |
| 2023-12-31 | €2755.17 | €30.40 | x |
| 2024-12-31 | €2871.53 | €30.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently KOBAYASHI PHARM utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.08%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 1.24x
- Recent ROE (4.72%) is below the historical average (9.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 10.31% | 10.12% | 0.72x | 1.42x | €482.00 Million |
| 2018 | 10.84% | 10.76% | 0.73x | 1.39x | €1.40 Billion |
| 2019 | 11.08% | 11.39% | 0.72x | 1.35x | €1.87 Billion |
| 2020 | 10.52% | 12.76% | 0.63x | 1.31x | €946.80 Million |
| 2021 | 10.08% | 12.70% | 0.61x | 1.29x | €155.10 Million |
| 2022 | 10.12% | 12.04% | 0.65x | 1.29x | €232.10 Million |
| 2023 | 9.93% | 11.73% | 0.65x | 1.31x | €-143.60 Million |
| 2024 | 4.72% | 6.08% | 0.62x | 1.24x | €-11.28 Billion |
Industry Comparison
This section compares KOBAYASHI PHARM's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $114,212,818,724
- Average return on equity (ROE) among peers: -9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| KOBAYASHI PHARM (KOY) | €208.24 Billion | 10.31% | 0.25x | $284.90K |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $989.01K |
| Tokyu Corporation (01T) | $779.37 Billion | 3.34% | 2.35x | $99.73K |
| GUANGZHOU AUTO -H- (02G) | $122.28 Billion | 6.59% | 0.55x | $4.05K |
| MOSAIC (02M) | $10.60 Billion | 4.43% | 0.90x | $280.83K |
| MOSAIC (02M.SG) (02M) | $9.56 Billion | 10.46% | 0.82x | $247.21K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $16.67 Million | -126.83% | 4.46x | $1.55 Million |
| KRAKATAU STEEL -B- (07K) | $552.59 Million | 3.52% | 4.72x | $166.99 |
| CN MODERN DAIRY (07M) | $7.12 Billion | -10.42% | 1.50x | $1.68K |
| TOURMALINE OIL (08T) | $7.22 Billion | 4.81% | 0.41x | $381.02K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $325.03 |